Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine microbiome and immune profiling study in relapsing-remitting multiple sclerosis
NL-OMON54765Recruiting
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Elisabeth-TweeSteden Ziekenhuis. Primary endpoint: Difference in gut and oral microbiome changes between responders and non-responders. Started Jan 2019; status: recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON54765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54765.